Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice. Their work establishes a next-generation gene-editing tool that enhances genetic manipulation for cancer and medical research in a preclinical model.

The study, “Advancing the genetic engineering toolbox by combining AsCas12a knock-in mice with ultra-compact screening,” was published in Nature Communications.

“This is the first time Cas12a has been used in preclinical models, which will greatly advance our genome engineering capabilities,” said co-author Eddie La Marca, PhD, a postdoctoral researcher at the Olivia Newton-John Cancer Research Institute (ONJCRI) in Australia.